(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine

ID: ALA301018

Chembl Id: CHEMBL301018

Cas Number: 153437-78-6

PubChem CID: 5329009

Max Phase: Preclinical

Molecular Formula: C16H13ClFN3O2

Molecular Weight: 333.75

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC

Standard InChI:  InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-9-3-4-12(18)11(17)5-9/h3-8H,1-2H3,(H,19,20,21)

Standard InChI Key:  VOPNWXZDJKCCRE-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA301018

   N-(3-chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 333.75

Molecular Weight (Monoisotopic): 333.0680

AlogP: 4.18

#Rotatable Bonds: 4

Polar Surface Area: 56.27

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.66

CX LogP: 3.89

CX LogD: 3.89

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.78

Np Likeness Score: -1.48

References

1. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L..  (2001)  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.,  11  (14): [PMID:11459659] [10.1016/s0960-894x(01)00344-4]

2. Wright SW, Hageman DL, McClure LD, Carlo AA, Treadway JL, Mathiowetz AM, Withka JM, Bauer PH..  (2001)  Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.,  11  (1): [PMID:11140724] [10.1016/s0960-894x(00)00586-2]

3. Gibson K, Grundy W, Godfrey A, Woodburn J, Ashton S, Curry B, Scarlett L, Barker A, Brown D.  (1997)  Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines,  7  (21): [10.1016/S0960-894X(97)10059-2]

4. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C..  (1999)  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.,  42  (26): [PMID:10639280] [10.1021/jm990345w]

5. Tasler S, Müller O, Wieber T, Herz T, Krauss R, Totzke F, Kubbutat MH, Schächtele C..  (2009)  N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping.,  19  (5): [PMID:19211246] [10.1016/j.bmcl.2009.01.054]

6. Garofalo A, Goossens L, Baldeyrou B, Lemoine A, Ravez S, Six P, David-Cordonnier MH, Bonte JP, Depreux P, Lansiaux A, Goossens JF..  (2010)  Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives.,  53  (22): [PMID:21033670] [10.1021/jm1009605]

7. Garofalo A, Goossens L, Six P, Lemoine A, Ravez S, Farce A, Depreux P..  (2011)  Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,  21  (7): [PMID:21353546] [10.1016/j.bmcl.2011.01.137]

8. Garofalo A, Farce A, Ravez S, Lemoine A, Six P, Chavatte P, Goossens L, Depreux P..  (2012)  Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.,  55  (3): [PMID:22229669] [10.1021/jm2013453]

9. Lü S, Zheng W, Ji L, Luo Q, Hao X, Li X, Wang F..  (2013)  Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.,  61  [PMID:22867529] [10.1016/j.ejmech.2012.07.036]

10. Waiker DK, Karthikeyan C, Poongavanam V, Kongsted J, Lozach O, Meijer L, Trivedi P..  (2014)  Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.,  22  (6): [PMID:24530227] [10.1016/j.bmc.2014.01.044]

11. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

12. Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L..  (2015)  Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.,  23  (22): [PMID:26526740] [10.1016/j.bmc.2015.10.035]

13. Gao H, Marhefka C, Jacobs MD, Cao J, Bandarage UK, Green J..  (2018)  ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.,  28  (15): [PMID:29945794] [10.1016/j.bmcl.2018.06.043]

14. Sidduri A, Dresel MJ, Knapp S..  (2023)  Incorporation of an Isohexide Subunit Improves the Drug-like Properties of Bioactive Compounds.,  14  (2.0): [PMID:36793427] [10.1021/acsmedchemlett.2c00476]

15. Kaur R, Dahiya L, Kumar M..  (2017)  Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.,  141  [PMID:29055870] [10.1016/j.ejmech.2017.09.029]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data